Abstract 5156
Background
Sarcoma constitutes a heterogeneous group of rare solid tumors and has no standard second-line treatment. Anti-angiogenesis tyrosine kinase inhibitors have shown promising efficacy for advanced sarcoma after failure of first-line chemotherapy. Apatinib is a highly selective vascular endothelial growth factor receptor 2 (VEGFR-2) antagonist from China. In the present study, we retrospectively assessed apatinib for safety and activity in advanced sarcoma patients from our cancer center.
Methods
Patients with advanced sarcomas treated with apatinib 250-500mg daily between August 2015 and February 2018 were retrospectively analyzed. Objective response was determined according to RECIST 1.1 criteria, progression-free survival (PFS) was estimated by the Kaplan-Meier curves and safety profile was analyzed.
Results
In total, 52 patients were treated with apatinib and 37 patients (23 males and 14 females) were included for analysis, including 7 alveolar soft part sarcoma (ASPS), 5 PNET/Ewing’s sarcoma, 4 osteosarcoma, 4 chondrosarcoma, 3 synovial sarcoma, 4 undifferentiated pleomorphic sarcoma, 4 leiomyosarcoma, 2 angiosarcoma,1 rhabdomyosarcoma, 1 chordoma, 1dedifferentiated liposarcoma and 1 clear cell sarcoma. 5 (13.5%) patients received apatinib as first-line treatment, 17 (45.9%) and 15 (40.5%) were treated with apatinib as second line or later therapy respectively.18 (48.6%) achieved tumor regression, 1 patient with ASPS had complete response, 8 (21.6%) experienced partial response, and disease was stable in 21 (56.8%) patients. The disease control rate was 100% in 5 patients with ASPS. The median PFS for all patients was 12 months, and median PFS of patients except ASPS was 5.9 m. The most frequent treatment-related adverse events included hypothyroidism [11 (29.7%)], Proteinuria [8 (21.6%)], hypertension [11 (29.7%)), hand-foot syndrome [19 (51.4%)], diarrhea [9 (24.3%)], fatigue [5 (13.5%)], hemorrhage [4 (10.8%)], anorexia [5 (13.5%)], oral ulcer [3 (5.4%)], rash [2 (8.1%)], bleaching hair [2 (5.4%)] and aerothorax [2 (5.4%)].
Conclusions
Apatinib may be effective and tolerable in advanced sarcoma, especially in ASPS.
Clinical trial identification
Legal entity responsible for the study
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.
Funding
Clinical Research Physician Program of Tongji Medical College, HUST.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4742 - Ki67 as an important predictor for Oncotype Dx Recurrence score risk groups in Early Breast cancer
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4697 - Genetic signatures always suggest undertreatment? Experience with PAM51
Presenter: Carolina Sales
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3158 - Significance of receptors expression, mitotic index and Ki67 in breast cancer patients with Nottingham Prognostic Index (NPI) poor prognosis score
Presenter: Mejri Nesrine
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3838 - Subgroup analyses of efficacy from a phase III study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab in early breast cancer patients
Presenter: Javier Cortes Castan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
715 - Autoimmunity and benefit from trastuzumab treatment in breast cancer: results from the HERA phase 3 trial
Presenter: Amir Sonnenblick
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2388 - Impact of hormone receptor status in HER2+ early breast cancer: a paradigm shift in the trastuzumab era
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3742 - Sefety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The french HERMIONE non-interventional prospective study
Presenter: jean-philippe Jacquin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3647 - Real-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancer.
Presenter: Rita De Sanctis
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3837 - Comprehensive evaluation of the pharmacokinetic profiles of SB3 and reference trastuzumab
Presenter: Xavier Pivot
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1692 - The impact of neoadjuvant dual HER2 targeting with Pertuzumab and Trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience
Presenter: Samantha Forner
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract